Article Sidebar

Download
PDF

Main Article Content

Abstract

The purpose of the present research was to develop a suitable simple and reproducible RP-HPLC method for a quantification of dapagliflozin propanediol in spiked human plasma samples. The liquid-liquid extraction plasma spiked samples of dapagliflozin propanediol were analyzed by using a ODS C18 Prontosil column under isocratic conditions. The extracted plasma spiked samples were carried using methanol, acetonitrile and pH 5.6 acetate buffer in the ratio of 50:20:10 (v/v) with a flow rate of 0.9 mL/min. The detector response was monitored at 228 nm using UV detector. The method was validated as per the ICH guidelines for bio analytical method validation and all the validation parameters were found to be within the acceptance limit The plasma spiked samples shows stability at room temperature over a period of 48 h. Thus, this method would be employed for routine quantification of dapagliflozin in human plasma samples.

Keywords

Dapagliflozin HPLC Bio-analytical Spiked plasma Stability study

Article Details

How to Cite
Subbareddy, P., & Divakar, T. (2019). Bio-analytical Development and Validation of RP-HPLC Liquid Method for Quantification of Dapagliflozin Propanediol in Spiked Human Plasma. Asian Journal of Organic & Medicinal Chemistry, 4(1), 28–31. https://doi.org/10.14233/ajomc.2019.AJOMC-P167
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Drug profile (2016); http://www.drugbank.ca/drugs/DBO6292.
  2. FDA Panel Advises Against Approval of DGPD Healio, 19 July (2011).
  3. FDA Approves Farxiga to Treat Type 2 Diabetes; Food and Drug Administration, 8 January (2014).
  4. US FDA Approves once-Daily XigduoTM XR Tablets for Adults with Type 2 Diabetes (2014).
  5. M. Sanagapati, K. Dhanalakshmi, G. Nagarjunareddy and S. Sreenivasa, Int. J. Pharm. Sci. Res., 5, 5394 (2014); https://doi.org/10.13040/IJPSR.0975-8232.5(12).5394-97.
  6. M.V. Verma, C.J. Patel and M.M. Patel, Development and Stability Indicating HPLC Method for Dapagliflozin in API and Pharmaceutical Dosage Form, Int. J. Appl. Pharm., 9, 33 (2017); https://doi.org/10.22159/ijap.2017v9i5.19185.
  7. S. Goday, A.R. Shaik and P. Avula, Development and Validation of a LC-ESI-MS/MS Based Bioanalytical Method for Dapagliflozin and Saxagliptin in Human Plasma, Indian J. Pharm. Educ. Res., 52(4s), S277 (2018); https://doi.org/10.5530/ijper.52.4s.108.
  8. N. Singh, P. Bansal, M. Maithani and Y. Chauhan, Development and Validation of a Stability-indicating RP-HPLC Method for Simultaneous Determination of Dapagliflozin and Saxagliptin in Fixed-Dose Combination, New J. Chem., 42, 2459 (2018); https://doi.org/10.1039/C7NJ04260D.
  9. Y. Mohammad, A Validated Stability Indicating High Performance Liquid Chromatographic Method for Simultaneous Determination of Metformin HCL and Dapagliflozin in Bulk Drug and Tablet Dosage Form, Asian J. Pharm. Clin. Res., 8, 320 (2015).
  10. A.-F. Aubry, H. Gu, R. Magnier, L. Morgan, X. Xu, M. Tirmenstein, B. Wang, Y. Deng, J. Cai, P. Couerbe and M. Arnold, Validated LC-MS/MS Methods for the Determination of Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor in Normal and ZDF Rat Plasma, Bioanalysis, 2, 2001 (2010); https://doi.org/10.4155/bio.10.139.
  11. M. Obermeier, M. Yao, A. Khanna, B. Koplowitz, M. Zhu, W. Li, B. Komoroski, S. Kasichayanula, L. Discenza, W. Washburn, W. Meng, B.A. Ellsworth, J.M. Whaley and W.G. Humphreys, in vitro Characteri-zation and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans, Drug Metab. Dispos., 38, 405 (2010); https://doi.org/10.1124/dmd.109.029165.
  12. K. Jadoon and I. Idris, Dapagliflozin: A Once-Daily Oral Therapy Sodium Glucose Cotransporter-2 Inhibitor for the Treatment of Adult Patients with Type 2 Diabetes, Clin. Med. Insights Ther., 3, 185 (2011); https://doi.org/10.4137/CMT.S6168.
  13. D.E. Kohan, P. Fioretto, W. Tang and J.F. List, Long-Term Study of Patients with Type 2 Diabetes and Moderate Renal Impairment Shows that Dapagliflozin Reduces Weight and Blood Pressure but Does Not Improve Glycemic Control, Kidney Int., 85, 962 (2014); https://doi.org/10.1038/ki.2013.356.
  14. J.P.H. Wilding, P. Norwood, C. T’joen, A. Bastien, J.F. List and F.T. Fiedorek, A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers, Diabetes Care, 32, 1656 (2009); https://doi.org/10.2337/dc09-0517.
  15. S. Mudaliar, R.R. Henry, G. Boden, S. Smith, A.-G. Chalamandaris, D. Duchesne, N. Iqbal and J. List, Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin, Diabetes Technol. Ther., 16, 137 (2014); https://doi.org/10.1089/dia.2013.0167.
  16. M. Aurora, E.R. Porrello, W. Tan, A.I. Mahmoud, J.A. Hill, R. Bassel-Duby, H.A. Sadek and E.N. Olson, Macrophages are Required for Neonatal Heart Regeneration, J. Clin. Invest., 124, 1382 (2014); https://doi.org/10.1172/JCI72181.
  17. S. Han, D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, S.A. Biller, J.R. Wetterau, W.N. Washburn and J.M. Whaley, Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats, Diabetes, 57, 1723 (2008); https://doi.org/10.2337/db07-1472.